<SEC-DOCUMENT>0001193125-16-754433.txt : 20161101
<SEC-HEADER>0001193125-16-754433.hdr.sgml : 20161101
<ACCEPTANCE-DATETIME>20161101061433
ACCESSION NUMBER:		0001193125-16-754433
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161031
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161101
DATE AS OF CHANGE:		20161101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAVITA INC.
		CENTRAL INDEX KEY:			0000927066
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				510354549
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14106
		FILM NUMBER:		161963182

	BUSINESS ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202
		BUSINESS PHONE:		310-536-2668

	MAIL ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA HEALTHCARE PARTNERS INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA INC
		DATE OF NAME CHANGE:	20001005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TOTAL RENAL CARE HOLDINGS INC
		DATE OF NAME CHANGE:	19950524
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d283677d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): October 31, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DAVITA INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>1-14106</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>No. 51-0354549</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2000 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Denver, CO 80202 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive offices including Zip Code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(303) 405-2100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 31, 2016, DaVita Inc. (the &#147;Company&#148;)
issued a press release regarding a policy change for Medicaid patients seeking Affordable Care Act plans, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be
deemed to be &#147;filed&#148; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in
any filing under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report
on Form 8-K and the document incorporated by reference herein contain or may contain statements that are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. The Company intends
these forward-looking statements to be covered by the safe harbor provisions for such statements. All statements that do not concern historical facts are forward-looking statements and include, among other things, statements about the Company&#146;s
expectations, beliefs, intentions and/or strategies for the future. These forward-looking statements include statements concerning the expected impact of the policy change described in Exhibit 99.1, including on future operating income and other
impacts of this policy change.&nbsp;These statements can sometimes be identified by the use of forward looking words such as &#147;may,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148;
&#147;expect,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;anticipate,&#148; &#147;plan,&#148; &#147;continue,&#148; &#147;seek,&#148; &#147;forecast,&#148; or &#147;intend&#148; or other similar words or expressions of the negative
thereof. These statements involve substantial known and unknown risks and uncertainties that could cause our actual results to differ materially from those described in the forward-looking statements, including, but not limited to the risk factors
set forth in Item 1A of the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2015, and its subsequent quarterly and annual reports and current reports on Form 8-K. The forward-looking statements should be considered in light
of these risks and uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company bases its forward-looking statements on information currently available to it at the time of this report.
The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors or circumstances, new information, future events or otherwise. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated October 31, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November 1, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DAVITA INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James K. Hilger</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James K. Hilger</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Interim Chief Financial Officer and Chief Accounting Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated October 31, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d283677dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g283677001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DaVita Announces Change for Medicaid </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patients Seeking Affordable Care Act Plan Coverage </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DENVER (Oct. 31, 2016) </B>&#150; DaVita Kidney Care (&#147;DaVita&#148;), a division of DaVita Inc. (NYSE: DVA), a leading provider in kidney care
services, today announced information concerning its patients enrolled in plans governed by the Affordable Care Act (&#147;ACA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With open
enrollment starting tomorrow, and in light of recent statements from the Centers for Medicare &amp; Medicaid Services (&#147;CMS&#148;), DaVita announced that, effective immediately, it will suspend support for applications to the American Kidney
Fund (&#147;AKF&#148;) for charitable premium assistance by patients enrolled in minimum essential Medicaid coverage who are seeking additional coverage on a 2017 ACA Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background and Patient Concerns </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. dialysis providers
are required to provide comprehensive education to their patients, including information regarding their insurance options and the availability of financial support, such as premium tax credits or charitable assistance.&nbsp;This requirement has
been in place since well before the ACA. DaVita has a disciplined, compliant process to provide this education to its patients. Since the implementation of the ACA in 2014, DaVita has included information about individual market plans in its patient
education.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the implementation of the ACA, a subset of DaVita&#146;s Medicaid patients have
opted to obtain additional coverage through ACA Plans. In pursuing this additional coverage, they were seeking &#150; and often obtained &#150; access to services beyond dialysis, including access to specialty physicians, more comprehensive drug
coverage, increased chance of qualifying for transplantation, and coverage for out-of-state services. While Medicaid patients are eligible to enroll in individual market plans, as confirmed in guidance by CMS<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>, only a small number have done so, and those who do typically rely on charitable premium assistance, from the AKF or otherwise, because they are ineligible for federal premium tax credits.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Individual market plans include both on-exchange and off-exchange plans (collectively &#147;ACA Plans&#148;). On-exchange plans, often referred to as &#147;Marketplace plans,&#148; are purchased through the federal or
state program and allow individuals to seek premium tax credits.&nbsp;Off-exchange plans are purchased directly from the issuers.&nbsp;Both impact the same risk pool and, as a result, the information provided here refers to both on-exchange and
off-exchange plans. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CMS&#146;s RFI and accompanying letter to dialysis facilities erroneously implied that it is unlawful to enroll a Medicaid beneficiary in an ACA Plan, citing to Social Security Act Section 1882(d)(3)(i)(II) in its
letter to dialysis facilities. In fact, that statute prohibits someone from selling a Medicare beneficiary unnecessary Medicare supplemental insurance that merely duplicates their existing coverage, and is inapplicable to this
situation.&nbsp;Further, Medicaid benefits are often limited; an ACA Plan is not merely duplicative of Medicaid; and CMS itself has repeatedly recognized that Medicaid beneficiaries <B>are</B> eligible to enroll in an ACA Plan, just not eligible for
federal premium tax credits or federal subsidies. <U>https://www.cms.gov/CCIIO/Programs-and-Initiatives/Health-Insurance-Marketplaces/Downloads/Complex-Sits-Webinar-FINAL.pdf</U>&nbsp;3/20/2016, page 26;
<U>https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/Downloads/PDM-Round-3-FAQ-8-1-16.pdf.</U> </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change announced today will affect approximately 2,000 patients, or about one percent of DaVita&#146;s total
patient population, who have pre-existing minimum essential Medicaid coverage and obtained additional coverage through ACA Plans. If CMS establishes a policy to restrict access by Medicaid patients to ACA Plans or the use of charitable assistance
for such plans, these patients likely will revert back to Medicaid-only coverage.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 3,000 additional DaVita patients are enrolled in an ACA
Plan and not in Medicaid.&nbsp;Most of these patients came to DaVita with individual market coverage or other commercial coverage already in place, and many are not eligible for any other type of coverage.&nbsp;About half of these patients access
charitable premium assistance, either in addition to or instead of premium tax credits.&nbsp;If charitable premium assistance were no longer available to them, thousands of dialysis patients across the U.S. are at risk of becoming uninsured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We were thrilled to present ACA coverage options to our patients, since for some of them this meant opportunities for much improved care,&#148; said
Kent Thiry, chairman and CEO of DaVita.&nbsp;&#147;While our analysis indicates that dialysis patients account for less than 2% of the overall medical costs in ACA Plans, we understand the financial pressures in the risk pool.&nbsp;We stand ready to
work with all stakeholders to preserve the intent of the ACA within a sustainable rate and regulatory structure.&nbsp;If CMS opts to restrict Medicaid patients&#146; access to ACA Plans, we are prepared to offer special rates for patients that CMS
and issuers are willing to grandfather, in order to avoid disruption and preserve their improved benefits and care.&#148;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Impact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because Medicaid reimburses for dialysis at a lower rate than ACA Plans, DaVita estimates that a policy change that prevents patients with minimum essential
Medicaid coverage from accessing charitable premium assistance to enroll in ACA Plans would result in a reduction in its annualized operating income of up to approximately $140 million before any offsets.&nbsp;If CMS were to issue a broader ruling
that made access to charitable premium assistance unavailable to all ESRD patients on ACA Plans, the estimated financial impact would increase by up to $90 million, based on our estimate that a significant number of ESRD patients would lose their
ACA coverage and end up completely uninsured, while others could continue the coverage with federal subsidies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DaVita looks forward to continuing a
collaborative dialogue with regulators and issuers on efforts to strengthen the sustainability of the ACA and continue to provide clarity and access to coverage for patients in the future.&nbsp;We will provide additional details on our third quarter
earnings call on Wednesday, November 2, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DaVita Kidney Care </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DaVita Kidney Care is a division of DaVita Inc., a Fortune 500<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> company that, through its operating
divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and
end stage renal disease. DaVita Kidney Care strives to improve patients&#146; quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30,
2016, DaVita Kidney Care operated or provided administrative services at 2,293 outpatient dialysis centers located in the United States serving approximately 185,000 patients. The company also operated 127 outpatient dialysis centers located in 11
countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company&#146;s leadership development initiatives and social responsibility
efforts have been </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit <U>DaVita.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>General Media</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Investor Relations</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kate Stabrawa</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jim Gustafson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">303-876-7527</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">310-536-2585</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Kate.stabrawa@davita.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">jim.gustafson@davita.com</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g283677001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g283677001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0 "W P$1  (1 0,1 ?_$ *X   (" 04!
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MT!?I!= ^WIMI<;OM=UL>YS[1>BEU;R%6\#X$>3"A7R(PQ=HW2UWK;8=UL_\
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MT8,1=YIYQ1XV\5,]YN4< @YQ]C.R2D)^H5$RUI>,SQ%1;$4-O^JYLT@U(4
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MS R@A_D<1'YZS?>W<]]>2WUP=4\TC.Q\6=B3_;C05E:16%G%90"D,,:HOL4
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8!HP8-&#!HP8-&#!HP8-&#!HP8-&#'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
